CA
NZ
UK
AU
IND
US
Last week, the Dow rose 1.05%, the S&P 500 climbed 1.22%, and the Nasdaq Composite jumped 2.21%, with all three indexes reaching new record highs. The rally was driven by the Fed’s expected 25-basis-point rate cut—its first since December—along with signals of two more …
U.S. stocks rose Thursday, with the Dow up 0.27%, the S&P 500 gaining 0.48%, and the Nasdaq climbing 0.94%, driven by strength in technology, industrials, and communication services. Intel surged 23% after Nvidia announced a $5 billion chip partnership, lifting Nvidia 3.5%, while Palantir, …
Skye Bioscience, Inc. (Nasdaq:SKYE), a clinical-stage biotechnology company developing therapies for obesity and metabolic health disorders, presented results from its Phase 1b study of nimacimab at the European Association for the Study of Diabetes (EASD) Annual Meeting. The trial evaluated nimacimab in subjects with …
CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.
Lam Research Corporation (NASDAQ:LRCX) reported results for the quarter ended June 29, 2025, showing sequential and year-on-year growth across revenue, earnings, and margins. Quarterly revenue reachedUS$5.171 billion, representing a 9.6% increase from the March quarter and a 33.6% rise compared to the same period …
US stocks swung on Wednesday after the Fed’s 25bps cut and guidance for two more reductions this year. The Dow gained over 300 points on strength in consumer staples and financials, while the S&P 500 and Nasdaq 100 edged lower as Nvidia and Broadcom …
Baker Hughes (NASDAQ:BKR) had its price target increased by Capital One Financial, which lifted its objective from USD 49.00 to USD 53.00 in a report issued Tuesday. The firm maintained an “overweight” rating, with the new price objective implying a potential upside of 12.13% …
Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) for the treatment of post-partum depression (PPD) in adults following childbirth. The decision makes ZURZUVAE the first and only treatment specifically indicated for PPD in the European …
In a move that was largely anticipated by Wall Street, the U.S. Federal Reserve's Federal Open Market Committee (FOMC) announced a quarter-percentage-point cut to the federal funds rate on September 17, 2025. This brings the new target range to 4% to 4.25%. The decision …
The Federal Reserve is expected to cut rates by 25 basis points, with markets focused on its outlook amid signs of a cooling labor market and subdued inflation. On Tuesday, U.S. equities slipped, with the Dow down 0.27%, the S&P 500 off 0.13%, and …
Please wait processing your request...